Related Experiment Video
Updated: Mar 1, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.9K
Concurrent hyperthermia and re-irradiation for recurrent high-grade gliomas
Neoplasma
|June 9, 2017
Summary
Salvage re-irradiation with hyperthermia is a safe and effective treatment for recurrent high-grade gliomas. This combination therapy offers a valuable option for patients with poor performance status.
Area of Science:
- Neuro-oncology
- Radiation Oncology
- Clinical Trials
Background:
- Recurrent high-grade gliomas (HGG) lack a standard salvage therapy.
- Surgery, radiotherapy, and chemotherapy are options, but efficacy is limited.
Purpose of the Study:
- To evaluate the tolerability and efficacy of re-irradiation (re-RT) combined with hyperthermia (HT) for recurrent HGG.
- To assess treatment compliance, toxicity, overall survival (OS), and progression-free survival (PFS).
Main Methods:
- Twenty patients with recurrent HGG received re-RT (30 Gy in 2 Gy fractions) with twice-weekly HT.
- Treatment compliance and toxicity were primary endpoints.
- OS and PFS were secondary endpoints.
Main Results:
- No significant acute morbidities over grade 3 were observed during re-RT with HT.
- Median OS from re-irradiation was 8.4 months (6-month survival: 67%, 12-month survival: 30%).
- Median PFS from re-irradiation was 4.1 months.
Conclusions:
- Concurrent re-RT with HT is a safe and well-tolerated salvage treatment for recurrent HGG.
- This combination may be a valuable option for selected recurrent HGG patients, particularly those with poor performance status.
